Markets open

Natera, Inc.

NTRA · Nasdaq

Analyst Consensus

Buy

14 analysts

$278

Current

—

Low

$295

Average

—

High

Average target implies +6.14% versus the current price.

The ratings synthesis for NTRA has not been generated yet.

Rating Actions

No individual rating actions have been captured for NTRAyet. Consensus figures above come from Nasdaq's aggregate feed.

Rating actions are extracted from published reporting. Each row links to its source.

Covering Firms

BAIRD R W

BTIG

GOLDMAN SACHS

GUGGENHEIM SEC.

JP MORGAN SECUR

LEERINK PARTNRS

MORGAN STANLEY

PIPER SANDLER

RAYMOND JAMES

SANFORD BERNSTE

STEPHENS INC

TD COWEN

UBS

WOLFE RESEARCH

Symbol: NTRA
Type: Stock
Sector: Health Care
Industry: Medical Specialities
Country: North America
Exchange: Nasdaq

Natera is a global leader in cell-free DNA and precision medicine, dedicated to oncology, women's health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera's tests are supported by more than 400 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California, and through Foresight Diagnostics, its subsidiary, operates an ISO 27001-certified and CAP-accredited laboratory certified under CLIA in Boulder, Colorado.